Jeil Pharmaceutical KRX:271980KOSPI

제일약품 · Korean news coverage and regulatory filings, organized.

Articles, 24h1
Articles, 7 days28
DART filings, 7 days0
Articles tracked113since Sep 11

In Q2 2026, Jeil Pharmaceutical reported revenue of ₩147bn, up 6.5% year on year, and an operating loss of ₩7.0bn. Jeil Pharmaceutical (제일약품) appeared in 28 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 28 with 25 articles. The most common catalyst was tech & capacity (1). It was most often mentioned alongside Hanmi Science and Jeil Pharma Holdings.

Filing signals Swung to loss Screener

Jeil Pharmaceutical quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩147bn+6.5%−₩7.0bn
margin −4.8%
−₩6.7bn
Q1 2026₩130bn-20.1%₩418m
margin 0.3%
₩3.2bn
Q4 2025 derived₩132bn-29.3%₩534m
margin 0.4%
₩9.5bn
Q3 2025₩135bn-22.7%₩9.8bn
margin 7.3%
₩15.9bn
Q2 2025₩138bn-20.5%₩4.7bn
margin 3.4%
₩3.0bn
Q1 2025₩163bn-4.3%₩5.7bn
margin 3.5%
₩3.6bn
Q4 2024 derived₩187bn+3.8%₩2.4bn
margin 1.3%
₩6.2bn
Q3 2024₩174bn-1.6%−₩4.1bn
margin −2.3%
−₩5.5bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Jeil Pharmaceutical top stories 2 weeks, by number of outlets

  1. 1
    제일약품·제일헬스사이언스, 백암공장서 재난대응 훈련
    13 outlets · 13 articlesFirst report Oct 28 08:48 메디포뉴스
  2. 2
  3. 3
    제일약품 자회사 온코닉 '자큐보 구강붕해정', 국제학술지에 연구 결과 게재
    1 outlets · 1 articlesFirst report Oct 23 08:58 더구루New technology
  4. 4
  5. 5
    "재난상황 대응 강화"…제일약품, 종합훈련 실시
    1 outlets · 1 articlesFirst report Oct 28 10:22 뉴시스경제
  6. 6

Latest Jeil Pharmaceutical news Korean headlines